Skip to main content
. Author manuscript; available in PMC: 2012 Sep 13.
Published in final edited form as: Cancer Cell. 2011 Sep 13;20(3):400–413. doi: 10.1016/j.ccr.2011.08.014

Figure 6. Rapamcyin/IPI-504 promotes regression of KrasG12D, p53-deficient NSCLC.

Figure 6

(A) MRI images of animals pre and post treatment as specified. The red circles highlight tumor masses. (B) Table listing the volumetric change of individual tumor masses as determined by MRI. (C) Waterfall plot depicting the reduction of total tumor volume in individual animals treated with rapamycin and IPI-504. (D) H&E stain of histological sections of the lung after 14 days of treatment (2×). (E) H&E stain of lesions from animals treated with vehicle, rapamycin, IPI-504 or rapamyin/IPI-504 for 2 weeks. Images b, d and f are enlargements of images a, c and e respectively. (See also Figure S6)